Prevalence of Nonalcoholic Fatty Liver Disease in the Middle Eastern Area: What Is the Exact Estimation?

Science Communicator Platform

Share By

Prevalence of Nonalcoholic Fatty Liver Disease in the Middle Eastern Area: What Is the Exact Estimation? Publisher Pubmed

Naderian M¹ ; Ebrahimi H¹ ; Sohrabpour AA¹

Source: Hepatology Published:2016

Abstract

[No abstract available]

Related Docs

View other Related Docs

1. Assessment of Lean Patients With Non-Alcoholic Fatty Liver Disease in a Middle Income Country; Prevalence and Its Association With Metabolic Disorders: A Cross-Sectional Study, Archives of Iranian Medicine (2017)

2. Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial, Nutrition and Metabolism (2018)

3. Patients With Psoriasis Are at a Higher Risk of Developing Nonalcoholic Fatty Liver Disease, Clinical and Experimental Dermatology (2015)

Experts (# of related papers)

View all Related Experts

Hossein Poustchi (3)

Amir Reza Radmard (1)

Other Related Docs

4. A Population-Based Prospective Study on Obesity-Related Non-Communicable Diseases in Northern Iran: Rationale, Study Design, and Baseline Analysis, Frontiers in Endocrinology (2024)

5. Effects of Vitamin D Supplementation on Liver Fibrogenic Factors in Non-Alcoholic Fatty Liver Patients With Steatohepatitis: Study Protocol for a Randomized Clinical Trial, Trials (2019)

6. Prevalence and Characteristics of Metabolic Dysfunction-Associated Fatty Liver Disease Among an Iranian Adult Population With Ethnic and Genetic Diversity: Results of the Polyiran-Liver Study, Middle East Journal of Digestive Diseases (2024)

7. Efficacy of Nanocurcumin Supplementation on Insulin Resistance, Lipids, Inflammatory Factors and Nesfatin Among Obese Patients With Non-Alcoholic Fatty Liver Disease (Nafld): A Trial Protocol, BMJ Open (2017)

8. The Effects of Green Cardamom on Blood Glucose Indices, Lipids, Inflammatory Factors, Paraxonase-1, Sirtuin-1, and Irisin in Patients With Nonalcoholic Fatty Liver Disease and Obesity: Study Protocol for a Randomized Controlled Trial, Trials (2017)

Style	Citing Format
MLA	Naderian M, Ebrahimi H, Sohrabpour AA. "Prevalence of Nonalcoholic Fatty Liver Disease in the Middle Eastern Area: What Is the Exact Estimation?." Hepatology, vol. 64, no. 4, 2016, pp. 1390-1391.
APA	Naderian M, Ebrahimi H, Sohrabpour AA (2016). Prevalence of Nonalcoholic Fatty Liver Disease in the Middle Eastern Area: What Is the Exact Estimation?. Hepatology, 64(4), 1390-1391.
Chicago	Naderian M, Ebrahimi H, Sohrabpour AA. "Prevalence of Nonalcoholic Fatty Liver Disease in the Middle Eastern Area: What Is the Exact Estimation?." Hepatology 64, no. 4 (2016): 1390-1391.
Harvard	Naderian M, Ebrahimi H, Sohrabpour AA (2016) 'Prevalence of Nonalcoholic Fatty Liver Disease in the Middle Eastern Area: What Is the Exact Estimation?', Hepatology, 64(4), pp. 1390-1391.
Vancouver	Naderian M, Ebrahimi H, Sohrabpour AA. Prevalence of Nonalcoholic Fatty Liver Disease in the Middle Eastern Area: What Is the Exact Estimation?. Hepatology. 2016;64(4):1390-1391.
BibTex	@article{ author = {Naderian M and Ebrahimi H and Sohrabpour AA}, title = {Prevalence of Nonalcoholic Fatty Liver Disease in the Middle Eastern Area: What Is the Exact Estimation?}, journal = {Hepatology}, volume = {64}, number = {4}, pages = {1390-1391}, year = {2016} }
RIS	TY - JOUR AU - Naderian M AU - Ebrahimi H AU - Sohrabpour AA TI - Prevalence of Nonalcoholic Fatty Liver Disease in the Middle Eastern Area: What Is the Exact Estimation? JO - Hepatology VL - 64 IS - 4 SP - 1390 EP - 1391 PY - 2016 ER -

Science Communicator Platform

Authors

Abstract